.png){kind=small}
.png){kind=small}
What
While public attention to vaccines soared throughout the global pandemic, innovation in the field has proceeded on many fronts and promises a bright future of possibilities. From RNA to protein-based technologies and other modalities, we stand poised to tackle acute and chronic infections, as well as tumors and autoimmune conditions, with a renewed arsenal to better serve clinicians and patients worldwide.
Questions We Discussed:
What are the most promising new technologies reshaping the immunological landscape? How can we better prepare for future infectious outbreaks and ensure better adherence? What lessons around vaccine misinformation can we use for a better public understanding of science in general?
Why
Who
The conversation was led by Jeremy Abbate of Scientific American and our own Why We Vax Chair, Sia Anagnostou. Learn the newest and future vaccine information from our panelists: Vivian Huang of Novavax, Phyllis Arthur of the Biotechnology Innovation Organization (BIO), and Ryan Morhard of Ginkgo Bioworks, Inc.
Previously recorded program available on LinkedIn.